Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

FATE – Fate Therapeutics, Inc.

Float Short %

7.46

Margin Of Safety %

Put/Call OI Ratio

0.51

EPS Next Q Diff

-0.01

EPS Last/This Y

0.49

EPS This/Next Y

-0.01

Price

1.16

Target Price

4.94

Analyst Recom

2

Performance Q

20.32

Relative Volume

0.67

Beta

2.22

Ticker: FATE



20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-13FATE0.98140.210.009126
2025-11-14FATE0.96010.220.009053
2025-11-17FATE0.99010.220.029006
2025-11-18FATE1.0250.210.079067
2025-11-19FATE1.060.2166.679229
2025-11-20FATE1.010.240.449415
2025-11-21FATE1.0250.220.289304
2025-11-24FATE1.0850.131.625040
2025-11-25FATE1.0550.16121.805139
2025-11-26FATE1.090.290.735752
2025-12-01FATE1.0250.383.856549
2025-12-02FATE1.0050.470.007512
2025-12-03FATE1.070.470.017588
2025-12-04FATE1.110.480.227442
2025-12-05FATE1.070.480.507452
2025-12-08FATE1.070.480.947455
2025-12-09FATE1.0550.520.218265
2025-12-10FATE1.070.510.488449
2025-12-11FATE1.1050.510.248479
2025-12-12FATE1.1550.510.278554
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1



20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-13FATE0.9829.5- -1.14
2025-11-14FATE0.9642.6- -1.14
2025-11-17FATE0.9842.6- -1.13
2025-11-18FATE1.0242.6- -1.13
2025-11-19FATE1.0542.6- -1.13
2025-11-20FATE1.0042.6- -1.13
2025-11-21FATE1.0237.6- -1.15
2025-11-24FATE1.0837.6- -1.15
2025-11-25FATE1.0637.6- -1.15
2025-11-26FATE1.0937.6- -1.15
2025-12-01FATE1.0237.6- -1.15
2025-12-02FATE1.0037.6- -1.15
2025-12-03FATE1.0837.6- -1.15
2025-12-04FATE1.1137.6- -1.15
2025-12-05FATE1.0837.6- -1.15
2025-12-08FATE1.0737.6- -1.15
2025-12-09FATE1.0537.6- -1.15
2025-12-10FATE1.0537.6- -1.15
2025-12-11FATE1.1137.6- -1.15
2025-12-12FATE1.1637.6- -1.15
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1



20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-13FATE-0.41-12.836.23
2025-11-14FATE-0.41-12.836.23
2025-11-17FATE-0.41-7.996.23
2025-11-18FATE-0.41-7.996.23
2025-11-19FATE-0.41-7.996.23
2025-11-20FATE-0.41-7.996.23
2025-11-21FATE-0.41-7.996.23
2025-11-24FATE-0.410.846.23
2025-11-25FATE-0.410.846.23
2025-11-26FATE-0.410.846.92
2025-12-01FATE-0.411.066.92
2025-12-02FATE-0.411.066.92
2025-12-03FATE-0.411.066.92
2025-12-04FATE-0.411.066.92
2025-12-05FATE-0.411.066.92
2025-12-08FATE-0.410.726.92
2025-12-09FATE-0.410.726.92
2025-12-10FATE-0.410.727.46
2025-12-11FATE-0.410.727.46
2025-12-12FATE-0.410.727.46
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

[stock_market_widget type="chart" template="candlestick" assets="FATE" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS​

-0.27

Avg. EPS Est. Current Quarter

-0.27

Avg. EPS Est. Next Quarter

-0.28

Insider Transactions

-0.41

Institutional Transactions

0.72

Beta

2.22

Average Sales Estimate Current Quarter

1

Average Sales Estimate Next Quarter

Fair Value

Quality Score

13

Growth Score

23

Sentiment Score

27

Actual DrawDown %

99

Max Drawdown 5-Year %

-99.4

Target Price

4.94

P/E

Forward P/E

PEG

P/S

18.58

P/B

0.57

P/Free Cash Flow

EPS

-1.32

Average EPS Est. Cur. Y​

-1.15

EPS Next Y. (Est.)

-1.16

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-2187.11

Relative Volume

0.67

Return on Equity vs Sector %

-93.6

Return on Equity vs Industry %

-78.6

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.05

EBIT Estimation

[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”FATE” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”FATE” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”FATE” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”FATE” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”FATE” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”FATE” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”FATE” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
Fate Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 181
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
stock quote shares FATE – Fate Therapeutics, Inc. Stock Price stock today
news today FATE – Fate Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch FATE – Fate Therapeutics, Inc. yahoo finance google finance
stock history FATE – Fate Therapeutics, Inc. invest stock market
stock prices FATE premarket after hours
ticker FATE fair value insiders trading